Suppr超能文献

丁丙诺啡治疗麻醉品成瘾:并非毫无风险。

Buprenorphine treatment for narcotic addiction: not without risks.

作者信息

Sansone Randy A, Sansone Lori A

机构信息

R. Sansone is a professor in the Departments of Psychiatry and Internal Medicine at Wright State University School of Medicine in Dayton, OH, and Director of Psychiatry Education at Kettering Medical Center in Kettering, OH. L. Sansone is a civilian family medicine physician at the Primary Care Clinic at Wright-Patterson Air Force Base in Dayton, OH. The views and opinions expressed in this article are those of the authors and do not reflect the official policy or position of the United States Air Force, Department of Defense, or United States Government.

出版信息

Innov Clin Neurosci. 2015 Mar-Apr;12(3-4):32-6.

Abstract

While most clinicians will never prescribe buprenorphine or combined buprenorphine/naloxone, familiarity with the risks of these pharmacological approaches to the treatment of narcotic addiction remains relevant. Overall, medication-assisted treatment has clearly resulted in meaningful gains for a number of individuals who are addicted to narcotics (i.e., opiates and opioids). However, a certain level of risk is inherent with these approaches. For example, both buprenorphine and buprenorphine/naloxone may be diverted and misused (e.g., intravenously injected, intranasally administered), particularly buprenorphine. Likewise, when illicitly injected, both can cause infectious complications as well as result in death from overdose. The risk of death with buprenorphine overdose appears to be heightened with the coadministration of either benzodiazepines or sedative/hypnotics. To conclude, as with all interventions in medicine, buprenorphine treatment for narcotic addiction has a clinically fluctuating risk/benefit equation that must be continually monitored.

摘要

虽然大多数临床医生永远不会开具丁丙诺啡或丁丙诺啡/纳洛酮复方制剂,但了解这些用于治疗麻醉品成瘾的药理学方法的风险仍然很有必要。总体而言,药物辅助治疗显然已使许多对麻醉品(即阿片类和阿片样物质)成瘾的人取得了显著成效。然而,这些方法存在一定程度的固有风险。例如,丁丙诺啡和丁丙诺啡/纳洛酮都可能被转移和滥用(如静脉注射、鼻内给药),尤其是丁丙诺啡。同样,非法注射时,两者都可能导致感染并发症以及因过量用药而死亡。丁丙诺啡过量用药导致死亡的风险在同时使用苯二氮䓬类药物或镇静/催眠药时似乎会增加。总之,与医学中的所有干预措施一样,丁丙诺啡治疗麻醉品成瘾的临床风险/效益平衡存在波动,必须持续监测。

相似文献

1
Buprenorphine treatment for narcotic addiction: not without risks.
Innov Clin Neurosci. 2015 Mar-Apr;12(3-4):32-6.
4
Buprenorphine-containing treatments: place in the management of opioid addiction.
CNS Drugs. 2006;20(9):697-712. doi: 10.2165/00023210-200620090-00001.
6
Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment.
Am J Drug Alcohol Abuse. 2018;44(4):488-496. doi: 10.1080/00952990.2018.1458234. Epub 2018 Apr 19.
8
Buprenorphine and naloxone interactions in methadone maintenance patients.
Biol Psychiatry. 1997 Jun 1;41(11):1095-101. doi: 10.1016/S0006-3223(96)00266-1.
9
Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?
Subst Use Misuse. 2016 Oct 14;51(12):1674-1679. doi: 10.1080/10826084.2016.1200097. Epub 2016 Jul 27.

引用本文的文献

1
A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder.
Drugs R D. 2023 Dec;23(4):339-362. doi: 10.1007/s40268-023-00443-5. Epub 2023 Nov 8.
4
Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.
Drug Alcohol Depend. 2020 Mar 1;208:107837. doi: 10.1016/j.drugalcdep.2020.107837. Epub 2020 Jan 9.
5
Buprenorphine-based opioid substitution therapy in India: A few observations, thoughts, and opinions.
Indian J Psychiatry. 2018 Jul-Sep;60(3):361-366. doi: 10.4103/psychiatry.IndianJPsychiatry_218_17.
6
Emerging Evidence for Cannabis' Role in Opioid Use Disorder.
Cannabis Cannabinoid Res. 2018 Sep 1;3(1):179-189. doi: 10.1089/can.2018.0022. eCollection 2018.
8
Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.
Drug Alcohol Depend. 2017 Jan 1;170:9-16. doi: 10.1016/j.drugalcdep.2016.10.039. Epub 2016 Nov 5.
10
Buprenorphine Maintenance for Opioid Dependence in Public Sector Healthcare: Benefits and Barriers.
J Addict Med Ther Sci. 2015;1(2):31-36. doi: 10.17352/2455-3484.000008. Epub 2015 Aug 3.

本文引用的文献

2
Misuse of medicines in the European Union: a systematic review of the literature.
Eur Addict Res. 2012;18(5):228-45. doi: 10.1159/000337028. Epub 2012 May 4.
3
Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome.
Forensic Sci Int. 2012 Jul 10;220(1-3):284-90. doi: 10.1016/j.forsciint.2012.03.016. Epub 2012 May 6.
4
Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France.
Drug Alcohol Depend. 2012 Nov 1;126(1-2):13-20. doi: 10.1016/j.drugalcdep.2012.03.009. Epub 2012 Apr 3.
5
The emerging buprenorphine epidemic in the United States.
J Addict Dis. 2012;31(1):3-7. doi: 10.1080/10550887.2011.642757.
6
Use and misuse of opioid replacement therapies: a Queensland study.
Subst Use Misuse. 2012 Jan;47(1):78-85. doi: 10.3109/10826084.2011.629017.
7
Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids.
Drug Alcohol Depend. 2012 May 1;122(3):201-7. doi: 10.1016/j.drugalcdep.2011.09.029. Epub 2011 Oct 28.
8
Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.
J Addict Med. 2011 Sep;5(3):175-80. doi: 10.1097/ADM.0b013e3182034e31.
9
Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.
Curr Drug Abuse Rev. 2011 Mar;4(1):28-41. doi: 10.2174/1874473711104010028.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验